A new study of iGlarLixi met its two primary endpoints and all key secondary endpoints in a head-to-head comparison against premixed insulin (biphasic insulin Aspart 30, BIAsp 30) in adults with ...
A high percentage of people with diabetes are deliberately letting their blood sugar reach high levels in a bid to avoid hypos, a new survey has found. The poll, carried out as part of Hypo ...
People with type 2 diabetes who use premix insulin (short- and intermediate-acting insulin in a single injection) to control high average blood sugar (HbA1c ≥9%) face a diminishing likelihood of ...
People with type 1 diabetes spent more nocturnal time in optimal blood sugar range and experienced lower glycemic excursions at night after switching from first-generation basal insulin analogs ...
Diabetes support programme relaunches to help plug COVID-19 hole in diabetes clinics Healthcare professionals can now refer people prescribed Toujeo onto a coaching programme to ensure they ...
Toujeo® (insulin glargine 300 units/mL) can now be used to treat children and teenagers with type 1 diabetes, pharmaceutical giant Sanofi has announced. The European Commission (EC) has approved ...
Children and adolescents with type 1 diabetes achieved comparable reduction in HbA1c and similar risk of low blood sugar events with Toujeo® (insulin glargine 300 Units/mL) compared to insulin ...
Heroes from the diabetes community were rewarded at the ninth annual Quality in Care (QiC) Diabetes Awards. More than 100 people attended the ceremony, which took place on the evening of ...
Sanofi has this week announced the UK launch of Suliqua™ (insulin glargine/lixisenatide) for the treatment of adults with type 2 diabetes. The drug is a once-daily, titratable, fixed-ratio ...
Abbott and Sanofi are partnering to integrate glucose sensing and insulin delivery technologies that would help to further simplify how people with diabetes manage their condition, it has been ...